VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★

PRICE: 0 CENTS

Tuesday, December 30, 2025

Altria Group, Inc.

MO · New York Stock Exchange

Market cap (USD)
SectorConsumer
CountryUS
Data as of
Moat score
88/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Altria is a U.S.-focused tobacco company with two reportable operating segments: Smokeable Products (cigarettes and machine-made cigars) and Oral Tobacco Products (moist smokeless tobacco and oral nicotine pouches), plus an 'all other' category that includes NJOY e-vapor and other smoke-free R&D/commercialization activities. The smokeable franchise is anchored by the Marlboro brand and recurring price increases in a concentrated U.S. cigarette market, though volumes continue to decline. The oral segment benefits from leading MST brands (Copenhagen, Skoal) and a meaningful position in nicotine pouches (on!), but faces category mix shift and competition (e.g., from other pouch brands). Smoke-free growth and protection depend heavily on FDA PMTA/MGO authorizations, while illicit products and litigation/patent outcomes can undermine economics.

Primary segment

Smokeable Products

Market structure

Oligopoly

Market share

45.9% (reported)

HHI:

Coverage

3 segments · 7 tags

Updated 2025-12-30

Segments

Smokeable Products

U.S. cigarettes and machine-made cigars

Revenue

88.3%

Structure

Oligopoly

Pricing

strong

Share

45.9% (reported)

Peers

BTIIMBBYVGR

Oral Tobacco Products

U.S. moist smokeless tobacco and oral nicotine pouches

Revenue

11.6%

Structure

Oligopoly

Pricing

strong

Share

37.5% (reported)

Peers

BTIPM

E-Vapor and New Products (NJOY, Horizon, R&D)

U.S. e-vapor (ENDS) and smoke-free product commercialization under FDA PMTA/MGO regime

Revenue

0.2%

Structure

Competitive

Pricing

weak

Share

5.5% (reported)

Peers

BTIPM

Moat Claims

Smokeable Products

U.S. cigarettes and machine-made cigars

Revenue_share computed from FY2024 segment net revenues ($21.204B smokeable of $24.018B total) per Altria segment reporting in its Form 10-K.

Oligopoly

Brand Trust

Demand

Strength: 5/5 · Durability: durable · Confidence: 4/5 · 2 evidence

Marlboro's long-running leadership and high retail share support premium positioning and shelf priority in U.S. cigarettes.

Erosion risks

  • Downtrading to discount brands during consumer income pressure
  • Menthol restrictions or bans impacting core SKUs
  • Accelerating conversion to smoke-free alternatives

Leading indicators

  • Marlboro retail share trend (total category and premium segment)
  • Premium vs discount mix and price-gap dynamics
  • Net price realization per pack vs industry inflation

Counterarguments

  • Brand loyalty can weaken as smokers downtrade or switch categories
  • Marketing restrictions limit new brand-building levers

Habit Default

Demand

Strength: 4/5 · Durability: medium · Confidence: 4/5 · 1 evidence

Nicotine dependence drives repeat consumption, which can reduce price sensitivity and support recurring purchase behavior (even as total smoker base declines).

Erosion risks

  • Public health measures reducing initiation and increasing cessation
  • Nicotine-cap regulation reducing product reinforcement
  • Social acceptability decline impacting consumption

Leading indicators

  • Industry volume decline rate vs historical trend
  • Quit/cessation rates and smoking prevalence data
  • Regulatory momentum on nicotine caps

Counterarguments

  • Addiction does not prevent category shrink; it mainly affects elasticity
  • Alternative nicotine formats can capture habitual consumption away from cigarettes

Benchmark Pricing Power

Financial

Strength: 4/5 · Durability: medium · Confidence: 4/5 · 1 evidence

The segment executes repeated list-price increases across major brands, suggesting strong category pricing power and ability to offset volume decline with price/mix.

Erosion risks

  • Price-gap widening drives downtrading and illicit trade
  • Excise tax increases reduce affordability
  • Retailer pushback on price/mix

Leading indicators

  • Net price realization vs volume decline
  • Discount share of category
  • Illicit cigarette prevalence indicators

Counterarguments

  • Pricing can accelerate downtrading and share losses
  • Illicit products can cap achievable price increases

Compliance Advantage

Legal

Strength: 3/5 · Durability: durable · Confidence: 4/5 · 1 evidence

The U.S. tobacco regulatory regime imposes substantial compliance and legal overhead. Scaled incumbents can spread these fixed costs and sustain regulatory engagement more effectively than small entrants.

Erosion risks

  • Regulation can be value-destructive (taxes, product bans) even if it raises barriers
  • Court/legal outcomes can change enforcement and product rules
  • Regulatory shifts may favor different product formats or competitors

Leading indicators

  • FDA rulemakings on flavors/menthol and product standards
  • Compliance costs as % of segment net revenues
  • Authorization cadence for new/modified products

Counterarguments

  • Regulation can constrain incumbents more than illicit competitors
  • Authorization pathways may still allow large competitors to catch up

Oral Tobacco Products

U.S. moist smokeless tobacco and oral nicotine pouches

Revenue_share computed from FY2024 segment net revenues ($2.776B oral of $24.018B total) per Altria segment reporting in its Form 10-K.

Oligopoly

Brand Trust

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence

Copenhagen and Skoal are established premium MST brands; together with on! pouches, the segment held a large retail share of the total oral tobacco category in 2024.

Erosion risks

  • Category mix shift from MST to nicotine pouches
  • Competitive intensity in pouches from larger global brands
  • Flavor restrictions impacting pouch growth

Leading indicators

  • Copenhagen and Skoal retail share trends
  • on! share within nicotine pouch subcategory
  • Oral category mix: pouch penetration vs MST

Counterarguments

  • Consumers may treat pouches as more substitutable than MST brands
  • Rapid innovation and marketing restrictions can limit differentiation

Benchmark Pricing Power

Financial

Strength: 4/5 · Durability: medium · Confidence: 4/5 · 1 evidence

Regular list-price increases across MST and pouch products indicate meaningful pricing power and ability to offset costs/inflation.

Erosion risks

  • Higher prices accelerate trade-down or switching to competitors
  • Illicit/unauthorized products undercut price umbrella
  • Retailer/promotional intensity increases

Leading indicators

  • Net price realization vs volume decline
  • Promotional spend as % of net revenues
  • Competitor price moves and price-gap tracking

Counterarguments

  • Pouch competition can force higher promotions, reducing effective pricing power
  • Price increases can be offset by mix shift toward lower-margin products

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: medium · Confidence: 4/5 · 2 evidence

FDA PMTA marketing authorizations can create a gating mechanism: authorized products can be legally marketed, while many competing products remain unauthorized and at higher enforcement risk. Helix (Altria) obtained PMTA authorizations for on! PLUS products in 2025.

Erosion risks

  • FDA enforcement remains inconsistent against unauthorized products
  • Future rule changes could tighten standards or limit flavors
  • Competitors also obtain authorizations, reducing differentiation

Leading indicators

  • Number and breadth of FDA-authorized nicotine pouch SKUs across industry
  • FDA enforcement actions against unauthorized pouch products
  • Timeline and outcomes of pending PMTA reviews

Counterarguments

  • Authorization does not guarantee consumer adoption or shelf space
  • If enforcement is weak, authorized status may not translate into economic advantage

E-Vapor and New Products (NJOY, Horizon, R&D)

U.S. e-vapor (ENDS) and smoke-free product commercialization under FDA PMTA/MGO regime

Revenue_share uses FY2024 'all other' net revenues ($0.038B of $24.018B total) reported by Altria; 'all other' includes NJOY, Horizon (heated tobacco JV), Helix International, and other R&D/new platform activities per the company's segment reporting.

Competitive

Regulated Standards Pipe

Legal

Strength: 3/5 · Durability: medium · Confidence: 4/5 · 3 evidence

In e-vapor, the ability to secure and maintain FDA marketing authorizations (MGOs via PMTA) can gate legal commercialization. NJOY reports its tobacco and menthol portfolio is covered by FDA marketing granted orders.

Erosion risks

  • Illicit disposables dominate share and weaken benefits of authorization
  • Patent litigation / import restrictions can disrupt supply
  • More competitors obtain PMTA/MGO authorizations

Leading indicators

  • FDA enforcement intensity against unauthorized e-vapor products
  • NJOY retail share trend in MULO+C channels
  • Legal outcomes affecting NJOY ACE supply chain/imports

Counterarguments

  • Regulatory authorization is necessary but not sufficient for consumer adoption and distribution
  • Weak enforcement can allow unauthorized competitors to capture most of the market

Evidence

sec_filing
Altria Form 10-K (FY ended 2024-12-31) - Business description (Marlboro leadership)

Marlboro ... has been the largest-selling cigarette brand in the United States for 50 years.

Direct statement of persistent brand leadership.

sec_filing
Altria Form 10-K (FY ended 2024-12-31) - Cigarette retail share (Circana/MSAi)

Marlboro 41.7% (2024).

Market share supports brand strength and consumer preference persistence.

other
Nicotine Is Why Tobacco Products Are Addictive (FDA)

Tobacco products are addictive because they contain nicotine.

Supports the behavioral 'habit/default' mechanism.

sec_filing
Altria Form 10-K (FY ended 2024-12-31) - Smokeable pricing actions

Effective October 20, 2024 ... increased the list price of Marlboro ... by $0.17 per pack.

Concrete evidence of repeated, broad-based pricing actions.

sec_filing
Altria Form 10-K (FY ended 2024-12-31) - Government regulations (FSPTCA/FDA authority)

FSPTCA provides the FDA with broad authority to regulate ... tobacco products.

Describes the breadth of FDA authority, implying high compliance burden/barriers.

Showing 5 of 16 sources.

Risks & Indicators

Erosion risks

  • Downtrading to discount brands during consumer income pressure
  • Menthol restrictions or bans impacting core SKUs
  • Accelerating conversion to smoke-free alternatives
  • Public health measures reducing initiation and increasing cessation
  • Nicotine-cap regulation reducing product reinforcement
  • Social acceptability decline impacting consumption

Leading indicators

  • Marlboro retail share trend (total category and premium segment)
  • Premium vs discount mix and price-gap dynamics
  • Net price realization per pack vs industry inflation
  • Industry volume decline rate vs historical trend
  • Quit/cessation rates and smoking prevalence data
  • Regulatory momentum on nicotine caps
Created 2025-12-30
Updated 2025-12-30

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.